Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment [Phase 1, Phase 2]

View source ↗

Summary

The NCI-announced Phase 1/2 trial testing magrolimab added to mogamulizumab for recurrent or refractory Mycosis Fungoides/Sezary Syndrome was terminated, with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mycosis Fungoides
• Sezary Syndrome

Drugs mentioned

• Magrolimab (magrolimab)
• Mogamulizumab (mogamulizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Mycosis Fungoides, Recurrent Mycosis Fungoides | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-10-16